Navigation Links
Paragon Bioservices Wins CMO Leadership Awards for Third Consecutive Year
Date:9/10/2013

BALTIMORE, Sept. 10, 2013 /PRNewswire/ -- Paragon Bioservices, a contract manufacturing organization whose expertise is the process development and manufacturing of biopharmaceuticals, announced today that it has been awarded the 2013 CMO Leadership Award for Quality and Reliability.

"We are very honored to receive this award from Life Science Leader -- especially because this is our third consecutive year," said Dr Marco Chacon, Paragon's CEO. "For more than twenty years, we have helped pharmaceutical and biotechnology companies and government agencies move forward in the development and manufacturing of vaccines (VLPs), monoclonal antibodies and therapeutic proteins.  We've completed two expansions in the past 4 years in order to constantly improve these capabilities.  Therefore, customer service, quality and reliability truly are key areas of focus at Paragon Bioservices.  The fact that we were recognized in the top 20% by more than 10,000 pharmaceutical executives is extremely gratifying to all of us at Paragon."

According to Jon Howland, Vice President of Publishing at Life Science Leader magazine, "These awards were conceived to better serve pharmaceutical and biopharmaceutical executives in their vetting process.  It gives them information on what their peers think of a wide range of CMOs and helps them to ultimately identify the leading CMOs in the industry."

ABOUT PARAGON BIOSERVICES, INC.
Paragon is a Contract Research & GMP Manufacturing Organization (CMO) delivering research, process development and manufacturing services. Paragon's focus is biopharmaceuticals -- including recombinant proteins, viral vectors, vaccines, VLPs, and bacteriophage. Our clients include pharmaceutical companies, biotechnology companies and federal agencies.  Our GMP space includes microbial and mammalian suites, fill-finish, and full
'/>"/>

SOURCE Paragon Bioservices, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine
2. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
3. Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching Commercialization
4. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
5. Berkeley Lab seeks to help US assert scientific leadership in critical materials
6. Auxilium Announces Appointments to Enhance Leadership Team
7. More than half of Americans doubt US global leadership in 2020
8. USC Marshall School of Business 6th Annual Leadership Summit
9. Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board
10. BioMotiv Launches Novel Drug Development Operation, Names Leadership Team
11. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital IQ ... Stock Report coverage on MabVax Therapeutics Holdings Inc . ... a clinical stage biotechnology company focused on the development ... needs in the treatment of cancer. MabVax has discovered ... the protective immune responses generated by patients who have ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)...  23andMe, the leading personal genetics company, today announced ... Officer and Corporate Counsel. Black brings a strong background ... as health care regulations. As a member of the ... reviewing, updating and enhancing the company,s privacy and consent ... joined the company January 5, 2015 and reports to ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the fiscal first quarter ... release are in Canadian dollars (CAD), unless otherwise stated. ... to win new business from our existing customers and ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 323andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... regenerative medicine company developing solutions based on the products of newborn ... Report as part of the 21st Century Breakthroughs for Biomedical Research ... ... -- Histogen, Inc., a regenerative medicine company developing solutions based on ...
... CITY, New Jersey, December 5, Rosetta Genomics, Ltd. (NASDAQ: ... microRNAs as biomarkers,reported today its consolidated financial results for ... The company recorded ... revenues were recorded from the date of acquisition of ...
... Bulletin Board: FVRL) and MyMedicalRecords.com, Inc. ("MMR"), a health,information ... Records (PHRs), announced today that two significant conditions,required for ... met. , (Logo: ... "We are pleased to announce that Favrille ...
Cached Biology Technology:Histogen Featured on Economic Report Television Series 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 3Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 4Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 5Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 6Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 7Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 8Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 9Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 10Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 2Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 3Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 4Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 5
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... a founding member of the Genome-Wide RNAi Global Initiative, ... to speed scientific and medical discoveries that target genes ... by Dharmacon, Inc. , manufacturer of the first ... interfering ribonucleic acid sequences. The library is designed to ...
... have helped eradicate and tame some of history's worst infectious ... vaccines can help overcome. The challenges society needs to ... plagues of the 21st century are the focus of a ... success of vaccines in controlling disease has been profound. ...
... of death among American men. It is estimated ... one in six males will develop the disease during his lifetime. However, ... disease. , One of the most innovative of these treatments is robotic-assisted ... is currently one of only ...
Cached Biology News:Yale participates in global human genome initiative 2Report focuses on challenges to unlocking future promise of vaccines 2Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 2Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 3
... Mouse monoclonal [YPF19] to Yersinia ... to detect Yersinia pestis . ... from Yersinia pestis vaccine ... This antibody recognises Y.pestis F1 capsular ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Biology Products: